20061-46-5

Basic information

• Product Name: 5-Benzothiazolecarboxaldehyde,2-methyl-(8CI,9CI)
• Synonyms: 5-Benzothiazolecarboxaldehyde,2-methyl-(8CI,9CI);2-Methyl-benzothiazole-5-carbaldehyde;2-Methyl-1,3-benzothiazole-5-carbaldehyde;2-Methyl-5-benzothiazolecarboxaldehyde
• CAS NO: 20061-46-5
• Molecular Formula: C₉H₇NOS
• Molecular Weight: 177.226
• Product Categories: BENZOTHIAZOLE
• Mol File: 20061-46-5.mol

Chemical Properties

• Melting Point: 100.5 °C(Solv: ligroine (8032-32-4))
• Boiling Point: 316.3±15.0 °C(Predicted)
• Appearance: /
• Density: 1.320±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.72±0.10(Predicted)
• CAS DataBase Reference: 5-Benzothiazolecarboxaldehyde,2-methyl-(8CI,9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Benzothiazolecarboxaldehyde,2-methyl-(8CI,9CI)(20061-46-5)
• EPA Substance Registry System: 5-Benzothiazolecarboxaldehyde,2-methyl-(8CI,9CI)(20061-46-5)

Safety Data

• Hazardous Substances Data: 20061-46-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-Benzothiazolecarboxaldehyde, 2-methyl-(8CI,9CI) is used as a key building block in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and properties allow for the development of new compounds with specific therapeutic or pesticidal effects.
Used in Dye, Perfume, and Flavoring Agent Industries:
This chemical compound is utilized as an intermediate in the production of dyes, perfumes, and flavoring agents. Its aromatic nature and reactivity contribute to the creation of a wide range of colorants, fragrances, and taste enhancers for various applications.
Used in Material and Product Development:
5-Benzothiazolecarboxaldehyde, 2-methyl-(8CI,9CI) may have potential applications in the development of materials and products for different industrial sectors. Its chemical properties and reactivity can be harnessed to create innovative materials with specific characteristics, such as improved stability, conductivity, or other desirable attributes.

Upstream product

• 32770-97-1 (2-methyl-1,3-benzothiazol-5-yl)methanol 
• 32770-98-2 2-methyl-5-benzothiazolecarxylic acid methyl ester 
• 74-11-3 para-chlorobenzoic acid 
• 125872-96-0 5-bromomethyl-2-methylbenzothiazole 
• 1006-99-1 2-methyl-5-chloro-benzothiazole 
• 646-06-0 1,3-DIOXOLANE 
• 95-26-1 2,5-dimethylbenzothiazole 
• 35350-37-9 methyl 4-[[4-(methoxycarbonyl)-2-nitrophenyl]disulfanyl]-3-nitrobenzoate 
• 14719-83-6 methyl 3-nitro-4-chlorobenzoate 
• 96-99-1 4-chloro-3-nitrobenzoate 
• 24851-69-2 2-methylbenzo[d]thiazole-5-carboxylic acid 

Downstream Products

• 50716-60-4 tetra-N-methyl-4,4'-(2-methyl-benzothiazol-5-ylmethanediyl)-bis-aniline 
• 20077-87-6 1-(2-methylbenzo[d]thiazol-5-yl)ethan-1-ol 
• 924727-12-8 (4S,5R,3'S)-4-methyl-5-phenyl-3-[3'-(2-methylbenzothiazol-5-yl)-3'-hydroxy-2'-oxopropyl]-2-oxazolidinone 
• 16251-45-9 (4S,5R)-4-methyl-5-phenyl-oxazolidin-2-one 
• 20077-88-7 1-(2-methylbenzo[d]thiazol-5-yl)ethan-1-one 
• 50716-64-8 bis-(4-dimethylamino-phenyl)-(2-methyl-benzothiazol-5-yl)-methinium; iodide 

Relevant articles and documents

Mild, Redox-Neutral Formylation of Aryl Chlorides through the Photocatalytic Generation of Chlorine Radicals

We report a redox-neutral formylation of aryl chlorides that proceeds through selective 2-functionalization of 1,3-dioxolane through nickel and photoredox catalysis. This scalable benchtop approach provides a distinct advantage over traditional reductive carbonylation in that no carbon monoxide, pressurized gas, or stoichiometric reductant is employed. The mild conditions give unprecedented scope from abundant and complex aryl chloride starting materials.

OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.

GLYCOSIDASE INHIBITORS

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND THEIR PREPA RATIONS

The present invention relates to novel 15-membered thiazole lactone or lactam polyketide compounds, their pharmaceutical compositions, their use and their preparations. The disclosed compounds relate to those of general formula I, their preparations and their use for preparing therapeutical compositions used as cell inhibitors.

EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND THEIR PREPARATIONS

The present invention discloses novel Epothilone analogues, their pharmaceutical compositions, their use and their preparations, especially discloses the compounds of general formula I, their preparations and their use for preparing therapeutical compositions used as cell inhibitors.

Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development

Going to trial: From about 350 active epothilone analogues synthesized by a highly convergent synthesis, one (ZK-EPO, see picture) has been chosen for clinical development on the basis of its outstanding preclinical data. This compound exhibits higher activity and efficacy than taxanes (e.g. paclitaxel) and second-generation epothilones, a fast and efficient cellular uptake, no recognition by efflux mechanisms, and an improved therapeutic window. (Chemical Equation Presented)

NOVEL BENSOPHENONE DERIVATIVES OR SALTS THEREOF

A benzophenone derivative represented by the following formula: whereinR1 represents, for example, an optionally substituted heterocyclic group, or a substituted phenyl group; Z represents, for example, an alkylene group; R2 represents, for example, a carboxyl group optionally protected with alkyl;R3 represents, for example, an optionally protected hydroxyl group; R4 represents, for example, an optionally substituted cycloalkyloxy group; and R5 represents, for example, a hydrogen atom, ???or a salt thereof has anti-arthritic activity, inhibits bone destruction caused by arthritis, and provides high safety and excellent pharmacokinetics and thus is useful as therapeutic agent for arthritis. These compounds have inhibitory effect on AP-1 activity and are useful as preventive or therapeutic agent for diseases in which excessive expression of AP-1 is involved.

Synthesis of a new spiropyran based on [60]fullerene unit

A new compound 2: spiropyran with [60]fullerene unit was synthesized and characterized by FT-IR, MALDI-TOF MS, NMR, and UV-Vis spectra.